Siegfried Holding AG (SFZN.SW) stock: key figures, P/E, revenue and dividend

Health Care · Switzerland · ISIN CH1429326825

Price
72.75 CHF
Market cap
3.20 bn CHF
P/E (2025)
18.87
P/S (2025)
2.41
Dividend yield
0.55 %
Net margin
12.66 %
Return on equity (ROE)
14.95 %
Return on assets (ROA)
7.84 %

Siegfried Holding AG financials

Fiscal year20242025
Revenue1.29 bn CHF1.33 bn CHF
Gross profit329.00 m CHF352.00 m CHF
Operating income199.36 m CHF223.33 m CHF
EBIT199.00 m CHF210.00 m CHF
Net income160.00 m CHF168.00 m CHF
Diluted EPS – continuing operations3.69 CHF3.85 CHF

Full history since 1997, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Siegfried Holding AG

Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.